Navigation Links
Laureate Biopharma Appoints Les Mintzmyer, Vice President, Operations
Date:2/14/2012

PRINCETON, N.J., Feb. 14, 2012 /PRNewswire/ -- Laureate Biopharmaceutical Services, Inc., a full-service biopharmaceutical contract development and manufacturing organization, today announced the appointment of Les Mintzmyer as Vice President, Operations. He will be responsible for continuing Laureate's transition to a full-scale commercial manufacturing operation. This will include preparing for upcoming pre-approval inspections at Laureate's Princeton facility, expanding production capacity with the commissioning of a new 2000L single-use bioreactor train, expanding Laureate's filling business in its freshly renovated filling facility, and planning for a new manufacturing facility. "Les brings a wealth of experience in managing every aspect of biopharmaceutical manufacturing operations," said Michael A. Griffith, Chief Executive Officer. "His combination of technical acuity and management savvy makes Les uniquely qualified to lead the continued expansion of our manufacturing operations to build our business."

(Logo: http://photos.prnewswire.com/prnh/20120214/PH53290LOGO )

Mr. Mintzmyer has more than 25 years of experience commissioning and operating full-scale biopharmaceutical manufacturing operations. Prior to joining Laureate as Vice President, Operations, Mr. Mintzmyer has served as Vice President, Manufacturing Operations for Avid BioServices, Senior Director, Manufacturing Operations at ImClone; Director, Operational Excellence and Director, Manufacturing for Genentech; and Director of Manufacturing at Bristol-Myers Squibb. As Director of Manufacturing at Bristol-Myers Squibb, he led the creation of a biologics manufacturing capability that obtained FDA licensure and launched Orencia® in 2005. Mr. Mintzmyer earned a Master of Science in Chemical Engineering and a Bachelor of Science in Chemical Engineering from Colorado State University, and a Bachelor of Science from the University of Nebraska at Kearney. For more information related to Laureate Biopharma's capabilities and ongoing improvements, please visit www.LBioS.com.

About Laureate Biopharmaceutical Services, Inc.

Laureate Biopharmaceutical Services, Inc. is a full-service biopharmaceutical contract development and manufacturing organization. Laureate Biopharma's scientists are expert in process development and cGMP production of therapeutic proteins, including monoclonal antibodies and Fc-fusion proteins. In addition, the company's portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and regulatory support. Laureate Biopharma has served a global client base from its Princeton, New Jersey facility since 1981, and is a portfolio company of Saints Capital, LLC. For more information, please visit www.LBioS.com.

About Saints Capital, LLC.

Saints Capital is a leading direct secondary acquirer of venture capital and private equity investments in emerging growth companies around the globe. It also makes traditional direct venture capital investments on a primary basis and, in special situations, in technology, healthcare, consumer and industrial companies in the United States. Founded in 2000, Saints provides liquidity for private investors in such markets as investment and commercial banks, buyouts, corporate venture capital and hedge funds. Saints has more than $1 billion of committed capital under management, over 50 completed portfolio transactions and investments in more than 200 companies. For more information, please visit www.saintsvc.com.

For more information, contact: Imara Charles, Ph.D., Director of Project Management, Laureate Biopharma, at (609) 919-3367 or info@LBioS.com, or visit www.LBioS.com.


'/>"/>
SOURCE Laureate Biopharmaceutical Services, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Laureate Pharma to Add More Manufacturing Capacity
2. Laureate Announces Manufacturing Agreement with Tolerx
3. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
4. Laureate Pharma Honored as Emerging Life Sciences Company of the Year
5. Nobel Laureates to Speak at Keystone Symposia RNA Silencing Conference
6. US Oncology Named 2009 Laureate by IDG Computerworld Honors Program
7. Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010
8. Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development
9. Laureate Pharma Elects New Board Member
10. Thomson Reuters Predicts Nobel Laureates
11. Laureate Pharma Welcomes Three New Members to Business Development Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 Good Start Genetics, ... has eclipsed the 130 million covered lives mark through ... of Texas . With newly signed ... continues to enjoy strong payor acceptance based on the ... programs and genetic counseling, its industry-leading customer care and ...
(Date:3/22/2017)... Mass. , March 22, 2017   iSpecimen ... today announced that Doctors Pathology Service (DPS), ... region of the United States , ... Delaware Health Information Network (DHIN) to make ... The novel program, announced in 2015 ...
(Date:3/22/2017)... , March 22, 2017 MarketNewsUpdates.com News ... ... conditions are being pressured as of late due to the ... pain management has a dramatic impact on patient,s quality of ... development activities for identifying new forms of opioid formulations that ...
(Date:3/22/2017)... 22, 2017   Boston Biomedical , an industry ... to target cancer stemness pathways, today announced its Board ... as Chief Executive Officer, effective April 24, 2017. ... Li , M.D., FACP, who has led Boston Biomedical ... his leadership, Boston Biomedical has grown from a "garage ...
Breaking Biology Technology:
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
(Date:2/28/2017)... -- News solutions for biometrics, bag drop and New ... At ... 16 March, Materna will present its complete end-to-end passenger journey, ... a real benefit for passengers. To accelerate the whole passenger ... point solutions to take passengers through the complete integrated process ...
(Date:2/26/2017)... 25, 2017  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announces the ... "Too often, too many offenders return ... jails are trying to tackle this ongoing problem ... and family members. While significant steps are underway, Securus ...
Breaking Biology News(10 mins):